Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
India needs to expand its local vaccine manufacturing and research to give better control over safety of these pharma ...
India should focus on enhancing local vaccine manufacturing and research for better control over safety, according to GTRI. They also suggest investigating adverse health events post-vaccination to ...
GTRI also suggested the government to launch an investigation to track all adverse health events post-vaccination as this ...
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...
Hosted on MSN1d
Which High-Risk Patients Should Get the RSV Vaccine?All three RSV vaccines -- GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA -- are FDA-approved for all adults age 60 and ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback